This suggests that while there is no evidence for sex-associated ligands of PSGs, the biological mechanisms of PSGs, particularly their interactions with the KRAS pathway and tumor immune system, may differ between male and female patients, with better prognostic benefit in female patients with lower expression of the PSG genes. The gene discussed is KRAS; the disease is neoplasm.